^
Association details:
Biomarker:No biomarker
Cancer:Diffuse Large B Cell Lymphoma
Drug:Rituxan Hycela (rituximab/hyaluronidase) (CD20 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with…Diffuse Large B-cell Lymphoma (DLBCL)… Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
Secondary therapy:
Chemotherapy; CHOP